Some APPs can neutralize Gram-negative bacterial toxins and lipopolysaccharides (LPSs) and prevent interaction with its receptor, the Toll-like receptor (TLR)-4, which is expressed in different cell types since the LPS-TLR4 interaction triggers a response that, in some cases, can become uncontrolled, producing inflammation and organ damage [4,7], hallmarks of neonatal sepsis, which is one of the leading causes of mortality in neonatal intensive care units (ICUs) [8,9]. Here, TLR4 is linked to Neonatal sepsis.